Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on July 29, 2020. The filing reports preliminary financial results for the quarter ended June 30, 2020, and announces the commencement of an underwritten public offering of common stock.
Key Financial Metrics
The filing text references preliminary financial results for the quarter ended June 30, 2020, contained in Exhibit 99.2, but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this document. The filing notes the company has a history of losses.
Material Changes and Events
- Capital Raise: The Company commenced an underwritten public offering of its common stock on July 29, 2020.
- Financial Disclosure: Preliminary estimated financial results for Q2 2020 were released and incorporated by reference.
- Investor Communication: An investor presentation was made available on the Company's website.
Outlook, Risks, and Management Commentary
Management provided forward-looking statements regarding the anticipated use of proceeds from the offering, the need for additional financing, and expectations regarding funds available under the CPRIT grant. The filing highlights significant risks, including:
- COVID-19 Impact: Potential effects on business operations, third-party relationships, and clinical trials.
- Financial Sustainability: Risks related to the ability to obtain sufficient financing and manage cash utilization.
- Regulatory and Clinical Risks: Uncertainty regarding drug development, regulatory approval, and the predictive nature of earlier trial results.
- Market Risks: Volatility in the market price of common stock and the ability to maintain Nasdaq listing.
Investor Verification Checklist
- Verify the specific preliminary financial figures (revenue, net loss, cash position) in Exhibit 99.2 as they are not listed in the main text.
- Review the press release (Exhibit 99.1) for details on the size, price, and terms of the underwritten public offering.
- Assess the status and funding certainty of the CPRIT grant mentioned in the risk factors.
- Confirm the impact of the COVID-19 pandemic on the timeline of ongoing clinical trials.